tiprankstipranks
Natera’s CIRCULATE data looks strong, says Piper Sandler
The Fly

Natera’s CIRCULATE data looks strong, says Piper Sandler

Piper Sandler analyst David Westenberg notes that Natera published its CIRCULATE study data in Nature, a top tier academic journal, on colorectal cancer MRD, which he thinks came in with good data, suggesting that Signatera is useful for determining whether to put patients on adjuvant chemotherapy. Westenberg would expect guideline inclusion in CRC to lead to meaningful impacts to ASPs, potentially to over $1,000. He also notes that about 30% of Signatera volume currently is related to CRC. Given this publication, Westenberg thinks NCCN guideline inclusion for Signatera in CRC is possible in late 2023. The analyst has an Overweight rating on the shares with a price target of $70.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NTRA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles